BACKGROUND ASCERT (American College of Cardiology Foundation and the Society of Thoracic Surgeons Collaboration on the Comparative Effectiveness of Revascularization Strategies) was a large observational study designed to compare the long-term effectiveness of coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) to treat coronary artery disease (CAD) over 4 to 5 years.
W hile death rates attributable to coronary artery disease (CAD) have declined in recent years, CAD remains (as it has for decades) the leading cause of death and disability in the United States and the Western world (1) . Whereas randomized controlled trials continue as the gold standard for comparing therapeutic choices, the available data may not be sufficient to support Services 100% denominator file data (10) . To further examine the comparative efficacy of CABG and PCI, we studied the relative costs and costeffectiveness of revascularization strategies using ASCERT data.
METHODS
STUDY SUMMARY. A complete description of the ASCERT study design and methods has been published previously (11) . Briefly, ASCERT was a large observational study designed to compare the long- QUALITY-ADJUSTED LIFE-YEARS. Life-years may be limited for comparison across studies and disciplines because a person in perfect health will derive more value for a life-year saved than a patient in impaired health will. This is addressed by calculating QALY. In ASCERT, QALY were calculated by multiplying Because the distribution of the differences for cost and effectiveness is typically skewed, the statistics of the difference were estimated by bootstrap analysis (17) .
To reduce treatment selection bias in this observational study, propensity score bin bootstrapping methods (PSBB) were used to estimate the 95% con- Carlo simulation was performed to derive the differences in QALY and mean cost between the 2 treatment groups (22) .
RESULTS
CLINICAL DATA SUMMARY. The study included a total of 189,793 patients, of whom 86,244 patients underwent CABG and 103,549 patients underwent PCI ( Table 1 ). There were significant differences between these groups in both demographic and clinical characteristics prior to adjustment. A matched analytic population (n ¼ 43,084 for each treatment group) was obtained via 1-to-1 matching in 3 or more decimals of propensity scores. Table 1 shows the comparison of baseline characteristics by treatment group with unadjusted data, adjusted by inverse probability weighted (IPW), and matched analytic population. Age, sex, and most clinical covariates were well balanced between the CABG and PCI groups for both IPW-adjusted data and matched analytic data. Note that the number of vessels diseased and urgent status were not balanced by the IPW-adjusted population, but were similar in the matched analytic population. Table 1 . A similar trend was seen in the matched analytic population (Online Table 3 ).
COST-EFFECTIVENESS ANALYSIS FOR FOLLOW-UP
AND LIFETIME. Figure 1A) . Figure 1B) . Using a common threshold such as $50,000 per QALY gained, results from both the PSBB-adjusted and matched analytic population approaches illustrated that CABG provided moderate to high probability of better clinical benefit, which means CABG will often be a costeffective strategy (Figure 2 ). SUBGROUP ANALYSIS. Subgroup lifetime costeffectiveness analyses were performed for the matched analytic population. Similar results were obtained for all patients via PSBB (not shown). The cost-effectiveness acceptability (CEA) curve for CABG versus PCI demonstrates that for the lifetime analysis, the matched analytic population curve rises more steeply than that for PSBB adjusted initially, but the 2 converge over a lifetime. The y-axis corresponds to the probability of observations below corresponding incremental cost-effectiveness (CE) ratio.
Results in
Abbreviations as in Figure 1 . Table 4 ) derived from other cardiovascular studies and resources such as the American Heart
Association Heart Disease and Stroke Statistical
Update (1) . Figure 5A The cost-effectiveness acceptability curve ( Figure   5B ) illustrates that the variation the ICER considered in this sensitivity analysis was greater than noted purely by the play of chance in the base case; specifically, compared with 21.0% of observations below $30,000 per QALY gained, and 100% below $50,000 per QALY gained for the base case, there was a 33% probability of CABG being cost-effective at the $30,000 threshold and 100% at the $50,000 threshold. The probability of CABG being dominated by PCI was <1%. Sensitivity trends were similar for all patients adjusted using the PSBB approach.
DISCUSSION
We performed a cost-effectiveness analysis of ASCERT; the main clinical results showed that there was a long-term survival advantage in older patients with nonemergent multivessel CAD who were selected to have CABG rather than PCI. The present economic analysis shows CABG is more expensive than PCI is, almost entirely due to the initial procedural costs (Central Illustration). It is reasonable to conclude that, after the study period, resource use and costs would largely track in parallel. A long-term survival advantage among patients in the CABG group was converted into QALY gained (Central Illustration), but the point estimates for the ICER for potential CABG benefit were below common benchmarks ( Tables 2 and 3) . limited. Despite these limitations, the results of our sensitivity analyses were robust, suggesting that the results are unlikely to be severely affected as long as there is a survival benefit of CABG in keeping with the ASCERT results.
Finally, there is no scientific basis for a threshold to establish whether a therapy is cost-effective. The commonly used threshold of $50,000 is an approximation of societal "willingness to pay."
CONCLUSIONS
This study shows that over a period of 4 years or longer, CABG is associated with better outcomes but at higher cost than PCI among older patients with 2or 3-vessel CAD. Under the assumption that our analysis has fully accounted for both measured and unmeasured confounding, in patients with stable ischemic heart disease, CABG will often be considered cost-effective at thresholds of $30,000 or $50,000/QALY. 
